同步加量调强放疗治疗胸上段食管癌患者的临床疗效  

Clinical efficacy of simultaneous integrated boost intensity-modulated radiotherapy in patients with upper thoracic esophageal carcinoma

作　　者：林逢春 杨红杰 赵阳 韩倩 LIN Fengchun;YANG Hongjie;ZHAO Yang;HAN Qian(Cancer Center,He’nan Provincial People’s Hospital(Zhengzhou University People’s Hospital),Zhengzhou 450000,He’nan,China)

机构地区：[1]河南省人民医院(郑州大学人民医院)肿瘤中心,郑州450000

出　　处：《癌症进展》2025年第2期171-173,177,共4页Oncology Progress

摘　　要：目的探讨同步加量调强放疗治疗胸上段食管癌患者的临床疗效。方法根据放疗方法的不同将80例胸上段食管癌患者分为对照组(n=41,常规调强放疗)和观察组(n=39,同步加量调强放疗)。比较两组患者的临床疗效、肿瘤标志物[转化生长因子-β1(TGF-β1)、鳞状细胞癌抗原(SCC-Ag)、癌胚抗原(CEA)]水平及不良反应发生情况。结果观察组患者的疾病控制率为76.92%,高于对照组患者的53.66%,差异有统计学意义(P﹤0.05)。治疗12周后,两组患者TGF-β1、SCC-Ag、CEA水平均低于本组治疗前,观察组患者TGF-β1、SCC-Ag、CEA水平均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者各不良反应发生率比较,差异均无统计学意义(P﹥0.05)。结论同步加量调强放疗对胸上段食管癌患者的治疗效果显著,可降低肿瘤标志物水平,且具有一定的安全性。Objective To explore the clinical efficacy of simultaneous integrated boost intensity-modulated radiotherapy in patients with upper thoracic esophageal carcinoma.Method According to different radiotherapy methods,80 patients with upper thoracic esophageal carcinoma were divided into control group(n=41,conventional intensity-modulated radiotherapy)and observation group(n=39,simultaneous integrated boost intensity-modulated radiotherapy).The clinical efficacy,tumor markers[transforming growth factor-β1(TGF-β1),squamous cell carcinoma antigen(SCC-Ag),carcinoembryonic antigen(CEA)]levels and adverse reactions were compared between the two groups.Result The disease control rate of the observation group was 76.92%,higher than 53.66%of the control group,and the difference was statistically significant(P<0.05).After 12 weeks of treatment,the levels of TGF-β1,SCC-Ag and CEA in both groups were lower than those before treatment,and the levels of TGF-β1,SCC-Ag and CEA in observation group were lower than those in control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidences of adverse reactions between the two groups(P>0.05).Conclusion Simultaneous integrated boost intensity-modulated radiotherapy has a significant effect in the treatment of patients with upper thoracic esophageal cancer,it can reduce the levels of tumor markers,and has a certain safety.

关 键 词：食管癌 同步加量调强放疗 临床疗效 不良反应 

分 类 号：R735.1[医药卫生—肿瘤]